Pfizer’s Xeljanz Benefits from Biologic Switching in Rheumatoid Arthritis, According to Spherix Global Insights
Download Report Overview Analysis of RA patients switched from one biologic/JAK to another brand in the past three months indicate that Xeljanz has the greatest net gains when switching occurs. May 12, 2016, Zug, Switzerland – Spherix Global Insights reveals that Xeljanz is carving a niche as a popular switch-to-agent in second and later lines […]
Psoriatic Arthritis Patients Play A Substantial Role in Biologic Switching Decisions. Cimzia and Otezla Benefit Most From Patient Involvement, According to Spherix Global Insights
Download Report Overview A recent survey conducted by Spherix Global Insights reveals that psoriatic arthritis (PsA) patients play an important role in the decision to switch to – and from – biologics/Otezla. Specifically, the RealWorld Dynamix™: Biologic & Otezla Switching in Psoriatic Arthritisreport finds that in two-thirds of patients who have recently switched brands, the patient […]
Pfizer’s Newly Approved Once-Daily Xeljanz XR Is Unlikely To Expand Overall Brand Use According To The Latest Rheumatology Report
Download Report Overview A recent survey conducted by Spherix Global Insights with U.S. rheumatologists (n=96) in February indicates that despite increased dosing options for Pfizer’s Xeljanz, most physicians do not anticipate their overall use of the JAK inhibitor to change. Though 28% foresee that the QD dosing option may increase their use of Xeljanz, 17% […]
New Study Indicates High Therapy Switching Rates for Multiple Sclerosis Patients in the US & EU, Benefitting Biogen’s Tecfidera, Novartis’ Gilenya & Sanofi’s Aubagio
Download Report Overview The research, based on analysis of over 2,100 patient records and input from over 400 neurologists, also reveals high anticipation and market opportunity for Roche’s ocrelizumab. April 14, 2016 – Zug, Switzerland – A recent study conducted by Spherix Global Insights found that the use of oral DMTs significantly increase at the expense […]
Takeda’s Entyvio Shifts the Treatment Paradigm in Inflammatory Bowel Disease (IBD)
Download Report Overview Nearly 80% of the gastroenterologists in the study cite recent changes in their IBD patient management, with the majority of biologic use in Moderate to Severe patients. Over 10% recently indicated using biologics earlier than before, over 30% are using more biologics and 20% started patients on Entyvio. April 12, 2016 – Zug, […]
Relypsa’s Veltassa Does Not Disappoint as Trial Increases Among US Nephrologists
Download Report Overview At three months post-launch, close to half of US nephrologists have prescribed Veltassa and the vast majority intend to increase their use in the near term, according to Spherix Global Insights, GmbH April 11, 2016 – Zug, Switzerland A recent survey conducted by Spherix Global Insights with 102 US nephrologists in late […]
Relypsa’s Launch of Veltassa™ Off to a Strong Start According to US Nephrologists
Download Report Overview At one month post-launch, one in five surveyed nephrologists has started to use Veltassa in clinical practice, according to Spherix Global Insights, GmbH February 11, 2016 – Zug, Switzerland A recent survey conducted by Spherix Global Insights with 101 US nephrologists in late January 2016, shows promising activity for Veltassa, the first […]
After a Lackluster Launch, Keryx’s Auryxia Appears to Be Moving in the Right Direction According to Spherix Global Insights Gmbh
Download Oct 14, 2015 – Zug, Switzerland – Feedback gathered from 300 US nephrologists in the last three releases of RealTime Dynamix: Bone and Mineral Metabolism, suggests that Auryxia is finally on the upswing. Despite strong buy-in to the benefits of Auryxia and a patient population that is largely above the target range for phosphorus, […]
Spherix Global Insight Gmbh Announces Acquisition of Rare Insights LLC
Download Acquisition expands high quality insights services to rare diseases and a focus on integrating the patient perspective into core offerings September 30, 2015 – Zug, Switzerland –In line with organizational strategy to offer unparalleled insights across professional and patient groups, Spherix Global Insights has acquired Rare Insights LLC, an insight and strategy group with […]
Payers Expected to Push Use of Sandoz’s Glatopa; Effectively Tying Neurologists’ Hands
Over 65% of neurologists believe that payers will make generic Copaxone a step edit in multiple sclerosis therapy, according to Spherix Global Insights, GmbH September 28, 2015 – Zug, Switzerland –Feedback gathered from 99 neurologists in the most recent release of RealTime Dynamix: Multiple Sclerosis reveals that the uptake of generic Copaxone will most likely […]
